Drug Profile
Infliximab biosimilar - Pfizer
Alternative Names: GP1111; Infliximab-Pfizer; Infliximab-qbtx; IXIFI; PF 06438179; PF 6438179; XILFYA; ZESSLYLatest Information Update: 29 Dec 2021
Price :
$50
*
At a glance
- Originator Pfizer
- Developer Pfizer; Sandoz
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
- Mechanism of Action Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Ankylosing spondylitis; Crohn's disease; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
Most Recent Events
- 29 Sep 2021 No development reported - Phase-III for Rheumatoid arthritis (Combination therapy, Treatment-experienced) in Jordan (IV)
- 29 Sep 2021 No development reported - Phase-III for Rheumatoid arthritis (Combination therapy, Treatment-experienced) in Mexico (IV)
- 29 Sep 2021 No development reported - Phase-III for Rheumatoid arthritis (Combination therapy, Treatment-experienced) in Morocco (IV)